Our mission
As a pioneer of highly-innovative precision radiotherapy products, BetaGlue’s mission is to bring easy-to-use and cost-effective life changing personalised treatment options for the benefit of solid tumour cancer patients worldwide.
For patients
YntraDose® will provide life changing therapies
For interventional radiologists
YntraDose® will provide an easy-to-use, safe and effective treatment option in the patient care pathway
For payers and healthcare providers
YntraDose® will provide a resource-efficient and cost-effective treatment option
Our team
BetaGlue® Therapeutics is led by a senior leadership team with more than a century of combined experience in growing companies and translating innovative oncology solutions through clinical trials and onto the market.
We are supported by an international board of directors with a strong track record of commercial success.
We are advised by globally recognised clinical Key Opinion Leaders in the fields of Interventional Radiology, Nuclear Medicine and Radiation Oncology from both Europe and the United States.
Leadership team
Dr. Colin Story
Chief Executive Officer (CEO)Current Non-Executive Director of Hox Therapeutics & Advisory Board Member of UKI2S Fund
Co-founder of OxSonics & OrthoSon
Former CEO OxSonics & Hox Therapeutics
Former roles at GE Healthcare & Oxford University Innovation
Pietro Bubba Bello
Head of Manufacturing & OperationsFormer Site Head, Director of Operations, and Plant Director of Operations and HSE Country Manager at Novartis
Former Site Head and Qualified Person and Head of Quality Control at Advanced Accelerator Applications
Gaia Bisaccioni
Head of RA/QAFormer Quality Site Head at Advanced Accelerator Applications
Former Quality Site Head & Deputy Qualified Person at Advanced Accelerator Applications
Dr. Betty Polikar
Head of Clinical Operations+ 25 years of experience in Clinical Development and Clinical Operations, during which different leading positions have been covered.
Formerly responsible for Start-Up Unit, Clinical Research Center of Excellence at Ospedale Pediatrico Bambino Gesù, Rome.
Formerly responsible for the Academic CRO of the Clinical Trial Center of the Fondazione Policlinico Gemelli, Rome.
Formerly responsible for strategic development pathways related to products (both drugs and medical devices) in different adult and pediatric indications.
Board of directors
Mike Cogswell
Chairman34 years of proven expertise in international healthcare leadership
Chairman of DermaCure RT & EbaMed SA
CEO & President of MagneTx Oncology Solutions Inc.
Managing Director of Mureva Phototherapy Inc.
Former SVP global sales ViewRay Inc., Mevion Medical Systems Inc. & Elekta Inc.
Dr. Michel Therin DVM, PhD
Independent Non-Executive DirectorPresident of MT2 Consulting
Former President Advanced Therapies at Siemens Healthineers
Former Global Vice President at Medtronic Minimally Invasive Therapies Group
Diana Saraceni
Investor Director (Panakès)Co-founder and Managing Partner of Panakes Partners
Former Co-founder and Managing Partner at 360 Capital
Mike Maszy
Investor Nominee Director25 years expertise in Operations, Engineering & New Product Development of Medical Devices
Former SVP Operations at Shockwave Medical (NASDAQ: SWAV)
Former VP Manufacturing at Endologix (NASDAQ: ELGX) & Trivascular (NASDAQ: TRIV)
Former leadership roles at Medtronic in Neurosurgery, Endovascular, Peripheral & Surgical Technologies
Clinical advisory board
Prof. Jafar Golzarian MD
Interventional RadiologistChairman of the advisory board
University of Minnesota Divisional Director IR & Vascular Imaging
Co-founder & President of GEST annual symposium
Prof. Roberto Iezzi MD
Interventional RadiologistAssociate Professor. Department of Radiology Universes Catolica
Director of Interventional Radiology at Policlinico Gemelli Rome
Prof. Marco Maccauro MD
Nuclear PhysicianAssociate Professor, of Nuclear Medicine at University of Milan.
Associate Director of Nuclear Department at National Cancer Institute Milan.
Our values
We are opening new frontiers in radiotherapy
Pioneering earlier, effective treatments for patients in an accessible and impactful way.
Driven by Precision: Leading with Data and Passion
Our ethos combines data-driven analysis, determination, and a passion to redefine radiotherapy. By embracing these qualities, we ensure our approach is innovative, informed, and resilient, making every advancement a step towards excellence.
Upholding Integrity: Ethical Excellence as Our Standard
Ethics, professionalism, and transparency guide our every step, forming the bedrock of our interactions with each other, our partners, patients and stakeholders. This unwavering commitment to integrity drives us to new frontiers in radiotherapy, building trust and dignity in all we do.
Innovation with Purpose: Constantly Improving Patient Outcomes
Our dedication to innovation focuses on improving patient outcomes, making each breakthrough a leap towards more effective and compassionate care. We’re committed to not just advancing radiotherapy as a science, but ensuring these advancements directly benefit those we serve, ensuring access and availability wherever we can.
Compassion in Action: Fostering Empathy and Inclusivity
Our revolutionary efforts in radiotherapy are fuelled by empathy and the celebration of diversity. By prioritizing understanding and mutual respect, we are creating an environment where innovation is driven by a genuine desire to improve lives.
Our partners
